ArticleJapanese journal of ophthalmology2026
Clinical course and efficacy of treatment with limbal-rigid contact lens wear for ocular sequelae in Stevens-Johnson syndrome/toxic epidermal necrolysis.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate the therapeutic efficacy of limbal-rigid contact lens (CL) wear in patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)-related ocular sequelae and to identify factors associated with visual acuity outcomes. STUDY
designRetrospective interventional case series.
methods20 patients (23 eyes) with stable SJS/TEN-related ocular surface disease underwent limbal-rigid CL therapy. Patients were stratified into two groups based on baseline best-corrected visual acuity (BCVA): Group 1 (logMAR >1.0, 16 eyes) and Group 2 (logMAR ≤1.0, 7 eyes). BCVA, subjective dryness scores, and objective ocular findings were assessed at baseline and at 1-, 3-, and 6-months post-initiation. Correlations between BCVA at 6 months and baseline ocular findings were analyzed. Bonferroni correction was applied for multiple comparisons.
resultsAll patients completed six months of CL wear without serious complications. Group 1 exhibited significant improvement in BCVA, from 1.65±0.45 to 0.98±0.52 immediately after CL wear, with sustained gains throughout follow-up (P < 0.01). Group 2 showed stable BCVA with moderate early effect sizes that did not reach statistical significance. Significant improvements in subjective dryness were observed only in Group 1. A moderate correlation between BCVA at 6 months and upper tarsal scarring was noted, although it did not reach statistical significance after correction.
conclusionsLimbal-rigid CL therapy appears safe and effective for visual rehabilitation in SJS/TEN-related ocular sequelae, particularly in severe cases. Upper eyelid scarring may influence visual outcomes and warrants further investigation.
Indexed as
Identifiers
41071482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.